Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: First clinical and laboratory experiences

Annals of the Rheumatic Diseases

Volumn 59, Issue SUPPL. 1, 2000, Pages

  Braun, J ^a   Radbruch, A ^a   Thiel, A ^a   Sieper, J ^a   Xiang, J ^a   Brandt, J ^a   Maetzel, H ^a   Haibel, H ^a   Wu, P ^a   Kohler, S ^a   Rudwaleit, M ^a   Siegert, S ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; HUMAN; LYMPHOCYTE COUNT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; SPONDYLITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033768521     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Prognosis, course of disease, and treatment of the spondyloarthropathies
2. Management of refractory ankylosing spondylitis and related spondyloarthropathies
3. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging
4. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
5. Nested PCR strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides
6. The sacroiliac joint in the spondyloarthropathies
7. Infliximab for the treatment of fistulas in patients with Crohn's disease
8. Ileocolonoscopy in seronegative spondyloarthropathy
9. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group
10. The role of TNF in health and disease
11. Regulation of autoimmunity by proinflammatory cytokines
12. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor a monoclonal antibody infliximab
13. Effects of chimeric monoclonal antibody to tumor necrosis factor-a (infliximab) in spondyloarthropathy: An open pilot study
14. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
15. Defining disease activity in ankylosing spondylitis: Is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropiate instrument
16. Treatment used by patients with ankylosing spondylitis. Comparison with the treatment preferences of rheumatologists
17. Anti-TNFα - A new dimension in the pharmacotherapy of SpA
18. Successful treatment of severe psoriasis arthritis with infliximab
19. Etanercept in the treatment of psoriatic arthritis and psoriosis: A randomised trial
20. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors
21. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: Many, but not all patients with sacroiliitis have spondyloarthropathy
22. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis
23. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis
24. Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo
25. Low T cell production of TNFα and IFNγ in ankylosing spondylitis: Its relation to HLA B27 and influence of the TNF-308 gene polymorphism
26. A low TNFα-secretion of peripher blood mononuclear cells but no other T helper 1 or 2 cytokines correlates with chronicity in reactive arthritis
27. Association of different tumor necrosis factor alpha promoter allele frequencies with ankylosing spondylitis in HLA-B27 positive individuals
28. Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis
29. The -308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27
30. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis
31. Long-term follow up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell counts in patients with rheumatoid arthritis after monoclonal anti-TNFa antibody therapy
32. Anti-TNF antibody treatment of Crohn's disease
33. Divergent T cell cytokine patterns in inflammatory arthritis
34. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis
35. Health-related quality of life in ankylosing spondylitis: A survey of 175 patients
36. The natural disease course of ankylosing spondylitis
37. The outcome of ankylosing spondylitis: A study of 100 patients
38. Predictive factors for the longterm outcome of spondyloarthropathies
39. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - Results from the German rheumatological database. German Collaborative Arthritis Centers
40. Radiologic scoring methods in ankylosing spondylitis: Reliability and sensitivity to change over one year
41. Radiologic diagnosis and pathology of the spondyloarthropathies
42. Inception cohort for early spondyloarthropathies